FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of Age and Older with pNET and epNET By Ogkologos - April 18, 2025 484 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CABINET study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Inavolisib June 26, 2025 FDA Approves Blood Tests That Can Help Guide Cancer Treatment October 15, 2020 Keanu Reeves Has A Long History Of Supporting Cancer Research January 13, 2022 Catch up on Behind the Science 2021 – From funding stream... May 17, 2021 Load more HOT NEWS ESMO 2024 Press Conference EMA Recommends Granting a Conditional Marketing Authorisation for Epcoritamab ASCO Annual Meeting 2023: Improving Patients’ Lives Through Collaboration, Research, and... Vitamin D Supplements Don’t Reduce Cancer Incidence, Trial Shows
